SG11201909735YA - Therapeutic compounds and compositions, and methods of use thereof - Google Patents
Therapeutic compounds and compositions, and methods of use thereofInfo
- Publication number
- SG11201909735YA SG11201909735YA SG11201909735YA SG11201909735YA SG 11201909735Y A SG11201909735Y A SG 11201909735YA SG 11201909735Y A SG11201909735Y A SG 11201909735YA SG 11201909735Y A SG11201909735Y A SG 11201909735YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- methods
- designated states
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 November 2018 (29.11.2018) WIPO I PCT mu °mons ono o VI IIIII onll oil Eno iflo oimIE (10) International Publication Number WO 2018/215389 Al (51) International Patent Classification: CO7D 487/04 (2006.01) A61K 31/519 (2006.01) A61P 29/00 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: (22) International Filing Date: PCT/EP2018/063262 Published: — with international search report (Art. 21(3)) 21 May 2018 (21.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/085276 22 May 2017 (22.05.2017) CN 62/640,865 09 March 2018 (09.03.2018) US (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). (72) Inventors: ZAK, Mark; c/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). ROMERO, F. An- thony; 3280 Bayshore Boulevard, Brisbane, CA 94005 (US). CHENG, Yun-Xing; 6 Tai-he Road, BDA, Beijing 100176 (CN). (74) Agent: SCHIRLIN, Julien; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 1-1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 00 11 el (54) Title: THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF (57) : Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharma- O ceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of \" treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017085276 | 2017-05-22 | ||
US201862640865P | 2018-03-09 | 2018-03-09 | |
PCT/EP2018/063262 WO2018215389A1 (en) | 2017-05-22 | 2018-05-21 | Therapeutic compounds and compositions, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909735YA true SG11201909735YA (en) | 2019-11-28 |
Family
ID=62386421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909735Y SG11201909735YA (en) | 2017-05-22 | 2018-05-21 | Therapeutic compounds and compositions, and methods of use thereof |
Country Status (19)
Country | Link |
---|---|
US (3) | US10307426B2 (en) |
EP (1) | EP3630766A1 (en) |
JP (2) | JP7256757B2 (en) |
KR (1) | KR20200010390A (en) |
CN (1) | CN110650959B (en) |
AU (1) | AU2018274577A1 (en) |
BR (1) | BR112019024322A2 (en) |
CA (1) | CA3061236A1 (en) |
CL (1) | CL2019003258A1 (en) |
CO (1) | CO2019010559A2 (en) |
CR (1) | CR20190520A (en) |
MA (1) | MA48942A (en) |
MX (1) | MX2019013308A (en) |
PE (1) | PE20200341A1 (en) |
PH (1) | PH12019502601A1 (en) |
RU (1) | RU2769696C2 (en) |
SG (1) | SG11201909735YA (en) |
TW (1) | TW201902896A (en) |
WO (1) | WO2018215389A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2769696C2 (en) * | 2017-05-22 | 2022-04-05 | Ф. Хоффманн-Ля Рош Аг | Therapeutic compounds and compositions and methods of using them |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
TW202115068A (en) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof |
JP2022537354A (en) * | 2019-06-18 | 2022-08-25 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES517193A0 (en) | 1981-11-10 | 1983-12-01 | Wellcome Found | A PROCEDURE FOR THE PREPARATION OF NEW IMIDAZO DERIVATIVES (4,5-C) PIRIDINA. |
US4847256A (en) | 1986-10-16 | 1989-07-11 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5705625A (en) | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
US7070972B1 (en) | 1995-01-13 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Janus family kinases and identification of immune modulators |
WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
US7091020B1 (en) | 1995-12-05 | 2006-08-15 | Incyte Corporation | Human Jak2 kinase |
ID18494A (en) | 1996-10-02 | 1998-04-16 | Novartis Ag | PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
FR2791562B1 (en) | 1999-03-29 | 2004-03-05 | Oreal | TINCTORIAL COMPOSITION CONTAINING PYRAZOLO- [1,5-A] - PYRIMIDINE AND A MONOCYCLIC POLYAMINOPYRIMIDINE AS OXIDATION BASES AND A COUPLER, AND DYEING METHODS |
YU25500A (en) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Process for the synthesis of nucleosite analogues |
EP1221444B1 (en) | 1999-07-02 | 2005-08-31 | Eisai Co., Ltd. | Fused imidazole compounds and remedies for diabetes mellitus |
CZ303875B6 (en) | 1999-12-10 | 2013-06-05 | Pfizer Products Inc. | Pyrrolo [2,3-d]pyrimidine compound and pharmaceutical composition in which the compound is comprised |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
EP1458682B1 (en) | 2001-12-20 | 2006-08-30 | Bayer HealthCare AG | 1,4-dihydro-1,4-diphenylpyridine derivatives |
CN100343255C (en) | 2002-04-23 | 2007-10-17 | 盐野义制药株式会社 | Pyrazolo (1,5-a) pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
AU2003270701B2 (en) | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
US20070270408A1 (en) | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
US7393873B2 (en) | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
SE0302487D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
CA2563305A1 (en) | 2004-04-09 | 2005-11-24 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
JP2007535560A (en) | 2004-04-28 | 2007-12-06 | シーブイ・セラピューティクス・インコーポレイテッド | A1 adenosine receptor antagonist |
MXPA06014637A (en) | 2004-06-25 | 2007-02-12 | Amgen Inc | Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases. |
NZ555236A (en) | 2004-11-04 | 2010-10-29 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
JP2009502734A (en) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Fused heterocycles as Lck inhibitors |
WO2007039797A1 (en) | 2005-10-03 | 2007-04-12 | Pfizer Products Inc. | Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis |
CA2624500A1 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
US7776865B2 (en) * | 2005-10-06 | 2010-08-17 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
CA2626742A1 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators |
WO2007065664A2 (en) | 2005-12-08 | 2007-06-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors |
US8541406B2 (en) | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
AR061793A1 (en) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | PIRAZOLO COMPOUND [1,5-A] PYRIMIDINE AND PHARMACEUTICAL COMPOSITION |
PE20080403A1 (en) | 2006-07-14 | 2008-04-25 | Amgen Inc | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
MX2009004715A (en) | 2006-10-30 | 2009-05-20 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents. |
US20080176870A1 (en) | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
EP2212297B1 (en) | 2007-10-12 | 2011-05-25 | Ingenium Pharmaceuticals GmbH | Inhibitors of protein kinases |
CA2707046A1 (en) | 2007-11-28 | 2009-06-11 | Nathanael S. Gray | Small molecule myristate inhibitors of bcr-abl and methods of use |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
CA2727036C (en) | 2008-06-20 | 2017-03-21 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
WO2010019762A1 (en) | 2008-08-13 | 2010-02-18 | Jenrin Discovery | Purine compounds as cannabinoid receptor blockers |
AU2009308675A1 (en) * | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine JAK inhibitor compounds and methods |
WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
CN102325765B (en) | 2009-02-06 | 2014-12-24 | 杨森制药公司 | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
TWI461425B (en) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
CN102666545B (en) | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor |
CA2793024A1 (en) | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
EA201291038A1 (en) | 2010-04-30 | 2013-05-30 | Целльзом Лимитид | PYRAZOL COMPOUNDS AS JAK INHIBITORS |
JP5985473B2 (en) | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pyrazolo [1,5a] pyrimidine and thieno [3,2b] pyrimidine derivatives as IRAK4 modulators |
WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
WO2012129258A1 (en) | 2011-03-22 | 2012-09-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
EP2892899B1 (en) | 2012-09-06 | 2018-03-21 | Bristol-Myers Squibb Company | Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
SG11201503517WA (en) | 2012-11-09 | 2015-06-29 | Jacobus Pharmaceutical Company Inc | Heteroaryl derivatives and uses thereof |
EP3019171B1 (en) | 2013-07-11 | 2018-09-05 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
EA201690952A1 (en) | 2013-11-08 | 2016-08-31 | Такеда Фармасьютикал Компани Лимитед | PYRAZOL FOR THE TREATMENT OF AUTOIMMUNE DISORDERS |
WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
EP3145522B1 (en) | 2014-05-23 | 2020-12-23 | Phibro Animal Health Corporation | Combination, composition, and method of administering the combination or composition to animals |
JO3701B1 (en) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
US9346815B2 (en) | 2014-05-23 | 2016-05-24 | Genentech, Inc. | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof |
CN107001379B (en) | 2014-11-06 | 2022-11-01 | Bial研发投资股份有限公司 | Substituted pyrazolo [1,5-a ] pyrimidines and their use in the treatment of medical disorders |
WO2016144846A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
WO2016144844A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of irak4 activity |
EP3268004B1 (en) | 2015-03-12 | 2019-12-18 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of irak4 activity |
WO2016144848A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrrolotriazine inhibitors of irak4 activity |
TW201720828A (en) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | Therapeutic compounds and compositions, and methods of use thereof |
WO2017140825A1 (en) | 2016-02-18 | 2017-08-24 | F. Hoffmann-La Roche Ag | Therapeutic compounds, compositions and methods of use thereof |
CR20190310A (en) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Pyrazolopyrimidine compounds and methods of use thereof |
WO2018166993A2 (en) | 2017-03-14 | 2018-09-20 | F. Hoffmann-La Roche Ag | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
EP3630767A1 (en) | 2017-05-22 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
RU2769696C2 (en) * | 2017-05-22 | 2022-04-05 | Ф. Хоффманн-Ля Рош Аг | Therapeutic compounds and compositions and methods of using them |
-
2018
- 2018-05-21 RU RU2019141734A patent/RU2769696C2/en active
- 2018-05-21 SG SG11201909735Y patent/SG11201909735YA/en unknown
- 2018-05-21 WO PCT/EP2018/063262 patent/WO2018215389A1/en active Application Filing
- 2018-05-21 KR KR1020197037532A patent/KR20200010390A/en unknown
- 2018-05-21 US US15/984,747 patent/US10307426B2/en active Active
- 2018-05-21 MA MA048942A patent/MA48942A/en unknown
- 2018-05-21 TW TW107117163A patent/TW201902896A/en unknown
- 2018-05-21 EP EP18727747.0A patent/EP3630766A1/en active Pending
- 2018-05-21 CN CN201880033741.6A patent/CN110650959B/en active Active
- 2018-05-21 MX MX2019013308A patent/MX2019013308A/en unknown
- 2018-05-21 PE PE2019001932A patent/PE20200341A1/en unknown
- 2018-05-21 JP JP2019564544A patent/JP7256757B2/en active Active
- 2018-05-21 AU AU2018274577A patent/AU2018274577A1/en not_active Abandoned
- 2018-05-21 CR CR20190520A patent/CR20190520A/en unknown
- 2018-05-21 BR BR112019024322-4A patent/BR112019024322A2/en not_active Application Discontinuation
- 2018-05-21 CA CA3061236A patent/CA3061236A1/en active Pending
-
2019
- 2019-04-17 US US16/387,187 patent/US20190240227A1/en not_active Abandoned
- 2019-09-27 CO CONC2019/0010559A patent/CO2019010559A2/en unknown
- 2019-11-14 CL CL2019003258A patent/CL2019003258A1/en unknown
- 2019-11-20 PH PH12019502601A patent/PH12019502601A1/en unknown
-
2020
- 2020-07-28 US US16/940,542 patent/US20200352951A1/en not_active Abandoned
-
2023
- 2023-02-14 JP JP2023020805A patent/JP2023058657A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201902896A (en) | 2019-01-16 |
BR112019024322A2 (en) | 2020-06-16 |
JP2020520959A (en) | 2020-07-16 |
CN110650959B (en) | 2023-04-18 |
PE20200341A1 (en) | 2020-02-14 |
EP3630766A1 (en) | 2020-04-08 |
RU2019141734A3 (en) | 2021-08-10 |
CR20190520A (en) | 2020-01-21 |
MX2019013308A (en) | 2020-02-12 |
US10307426B2 (en) | 2019-06-04 |
CA3061236A1 (en) | 2018-11-29 |
CO2019010559A2 (en) | 2019-10-09 |
PH12019502601A1 (en) | 2020-06-08 |
KR20200010390A (en) | 2020-01-30 |
MA48942A (en) | 2020-04-08 |
US20190240227A1 (en) | 2019-08-08 |
CL2019003258A1 (en) | 2020-04-17 |
JP2023058657A (en) | 2023-04-25 |
AU2018274577A1 (en) | 2019-10-10 |
RU2769696C2 (en) | 2022-04-05 |
CN110650959A (en) | 2020-01-03 |
RU2019141734A (en) | 2021-06-23 |
US20200352951A1 (en) | 2020-11-12 |
WO2018215389A1 (en) | 2018-11-29 |
JP7256757B2 (en) | 2023-04-12 |
US20180333416A1 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201407200TA (en) | Liquid formulation | |
SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201809764XA (en) | Humanized anti-il-1r3 antibodies |